Findings

What do systematic reviews say?

102 questions · 102 findings · 46 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 56 · 54.9%GRADE not reported 10 · 9.8%Very low 14 · 13.7%Low 15 · 14.7%Moderate 4 · 3.9%High 3 · 2.9%

Non‐platinum therapies vs platinum combination

QoL · non‐small cell lung cancer in the elderly population

1 finding from 1 review

Chemotherapy for advanced non‐small cell lung cancer in the elderly population 2015 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 5 participants
GRADE not reported

Non‐platinum single‐agent vs non‐platinum combination treatment

QoL · non‐small cell lung cancer in the elderly population

1 finding from 1 review

Chemotherapy for advanced non‐small cell lung cancer in the elderly population 2015 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 2 participants
GRADE not reported

Pilocarpine vs no treatment/placebo

Quality of life (McMaster HNRQ, 1-7 scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

It is very uncertain whether pilocarpine changes quality of life (McMaster HNRQ, 1-7 scale) compared with no treatment/placebo (very low certainty).

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
Up to and including 6 months postRT
MD 0.20 [-0.19, 0.59]
1 study · 90 participants
Very low

Antimicrobial lozenge vs placebo

Quality of life and other oral related symptoms · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
Over 6 months
Insufficient evidence of a difference for global quality of life, mouth pain RR 0.94 (95% CI 0.66 to 1.33), sore/burning mouth RR 0.95 (95% CI 0.68 to 1.35), throat pain RR 0.79 (95% CI 0.56 to 1.12) (Duncan 2005)
1 study
GRADE not reported

Intervention not reported

Quality of life not reported · Patients with refractory/relapsed Hodgkin lymphoma

1 finding from 1 review

High‐dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin… 2013 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

Gemcitabine plus cisplatin vs S‐1 plus cisplatin

Health‐related quality of life · people with advanced biliary tract carcinomas

The review found no eligible studies for this question.

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gemcitabine plus S‐1 vs S‐1

Health‐related quality of life · people with advanced biliary tract carcinomas

The review found no eligible studies for this question.

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gemcitabine plus oxaliplatin vs best supportive care

Health‐related quality of life · people with advanced biliary tract carcinomas

The review found no eligible studies for this question.

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gemcitabine plus vandetanib vs vandetanib

Health‐related quality of life · people with advanced biliary tract carcinomas

The review found no eligible studies for this question.

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gemcitabine plus oxaliplatin vs 5‐fluorouracil plus folinic acid

Helath‐related quality of life · people with advanced biliary tract carcinomas

The review found no eligible studies for this question.

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gemcitabine plus oxaliplatin vs 5‐fluorouracil plus cisplatin plus radiotherapy

Health‐related quality of life · people with advanced biliary tract carcinomas

The review found no eligible studies for this question.

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gemcitabine plus mitomycin C vs capecitabine plus mitomycin C

Health‐related quality of life · people with advanced biliary tract carcinomas

The review found no eligible studies for this question.

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Gemcitabine vs vandetanib

Helath‐related quality of life · people with advanced biliary tract carcinomas

The review found no eligible studies for this question.

1 finding from 1 review

Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Health‐related quality of life · people with non‐rhabdomyosarcoma soft tissue sarcoma

The review found no eligible studies for this question.

1 finding from 1 review

Autologous hematopoietic stem cell transplantation following high‐dose chemotherapy for nonrhabdomyosarcoma soft… 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Prophylactic platelet transfusion at threshold of 10,000 vs higher transfusion threshold (20,000 or 30,000)

Quality of life ‐ not reported · People with a haematological disorder

The review found no eligible studies for this question.

1 finding from 1 review

Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for… 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Prophylactic platelet transfusions with low‐dose schedule vs high‐dose schedule

Quality of life ‐ not reported · People with a haematological disorder

The review found no eligible studies for this question.

1 finding from 1 review

Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders… 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Prophylactic platelet transfusions with high‐dose schedule vs standard‐dose strategies

Quality of life ‐ not reported · People with a haematological disorder

The review found no eligible studies for this question.

1 finding from 1 review

Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders… 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Prophylactic platelet transfusions with low‐dose schedule vs prophylactic platelet transfusions with standard‐dose schedule

Quality of life ‐ not reported · People with a haematological disorder

The review found no eligible studies for this question.

1 finding from 1 review

Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders… 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Amifostine vs no treatment/placebo

Quality of life (Patient Benefit Questionnaire, 10-point scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

It is very uncertain whether amifostine changes quality of life (Patient Benefit Questionnaire, 10-point scale) compared with no treatment/placebo (very low certainty).

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
12 months postRT
MD 0.70 [0.20, 1.20]
1 study · 180 participants
Very low

Selenium vs no intervention

Quality of life and other oral related symptoms (loss of taste, dysphagia) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region

1 finding from 1 review

Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
6 weeks after end of RT
Insufficient evidence of differences for loss of taste or dysphagia; data largely unusable (no standard deviations). Ageusia milder in selenium group (not significant); dysphagia significant only at week 7 (P = 0.05)…
1 study
GRADE not reported